Combination of BA-210 and digestion of the glial scar in chronic spinal cord injury

BA-210 与慢性脊髓损伤中胶质疤痕消化的结合

• 批准号: 8832809
• 负责人: Lisa J McKerracher
• 金额: $ 31.92万
• 依托单位: BIOAXONE BIOSCIENCES, INC.
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-03-01 至 2017-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8832809
• 关键词: Acute; Agglutinins; American; Animals; Antibodies; Arylsulfatase B; Axon; Biological Assay; Blood - brain barrier anatomy; Cervical spinal cord injury; Chondroitin ABC Lyase; Chondroitin Sulfate Proteoglycan; Chronic; Cicatrix; Clinical; Clinical Research; Clinical Treatment; Clinical Trials; Combined Modality Therapy; Corticospinal Tracts; Development; Digestion; Dose; Drug Combinations; Drug Targeting; Effectiveness; Enzyme-Linked Immunosorbent Assay; Enzymes; Epitopes; Evaluation; Functional disorder; GAG Gene; Glial Fibrillary Acidic Protein; Goals; Guanosine Triphosphate Phosphohydrolases; Hand; Histology; Human; Immune response; Injection of therapeutic agent; Investigational Drugs; Label; Lectin; Lesion; Life; Marketing; Measures; Modeling; Monitor; Movement; Mus; Natural regeneration; Nervous System Trauma; Neuraxis; Neurons; Outcome; Paralysed; Patients; Pharmaceutical Preparations; Phase; Pump; Quality of life; Rattus; Recovery; Recovery of Function; Route; Safety; Signal Transduction; Site; Small Business Innovation Research Grant; Sodium Dodecyl Sulfate-PAGE; Spinal Cord; Spinal cord injury; Staining method; Stains; System; Temperature; Testing; Topical application; Wisteria; aggrecan; arm; axon regeneration; collagenase; effective therapy; efficacy testing; functional outcomes; immunocytochemistry; improved; injured; monocyte; mouse model; prevent; public health relevance; repaired; research study; rho; scaffold

DESCRIPTION (provided by applicant): BA-210 is an investigational drug that targets Rho, an intracellular GTPase important for controlling axon regeneration and repair after spinal cord injury. BA-210 has completed a Phase I/IIa clinical trial for treatment of acute spinal cord injury in 48 patients. Not only was BA-210 safe and well tolerated, but patients with cervical SCI showed very promising recovery of arm and hand movements. While current development is to treat acute spinal cord injury, BA-210 has potential to improve outcome in patients with chronic SCI, especially if used in combination with other therapies. One barrier to treating chronic SCI is the glial scar that develops and remains after SCI. Several drugs currently on the market have the potential to digest the glial scar and could be repurposed for SCI. Combining BA-210 with a repurposed drug will accelerate the regulatory path to clinical trials and approval. The overall goal of this SBIR project is to investigate the use of BA-210 in combination with one of two drugs that digest the glial scar as a treatment for chronic SCI.

描述（由申请人提供）：BA-210是一种针对Rho的研究药物，Rho是一种细胞内GTPase，对于控制脊髓损伤后轴突再生和修复很重要。 BA-210已完成I/IIA期临床试验，用于治疗急性脊髓损伤 在48位患者中。 BA-210不仅安全且耐受性良好，而且宫颈SCI患者的手臂和手动运动恢复非常有前途。尽管目前的发育是治疗急性脊髓损伤，但BA-210有可能改善慢性SCI患者的预后，尤其是与其他疗法结合使用时。治疗慢性SCI的一个障碍是 在科幻之后出现并保留的神经胶质疤痕。目前市场上的几种药物有可能消化神经胶质疤痕，可以重新用于SCI。将BA-210与重新利用的药物相结合将加速临床试验和批准的调节途径。该SBIR项目的总体目标是研究BA-210与消化神经胶质疤痕作为慢性SCI治疗的两种药物之一的使用之一。